Literature DB >> 25986165

French recommendations for the prevention of 'emerging extensively drug-resistant bacteria' (eXDR) cross-transmission.

D Lepelletier1, P Berthelot2, J-C Lucet3, S Fournier4, V Jarlier5, B Grandbastien6.   

Abstract

Controlling the spread of multi- or extensively drug-resistant bacteria (MDR or XDR) includes a dual strategy for reducing antibiotic prescriptions and preventing their spread from patient carriers. Standard precautions are applicable to all health professionals caring for any patients; additional barrier precautions (isolation) are recommended for patients carrying transmissible infectious diseases or MDR bacteria in sporadic or epidemic situations. Moreover, additional precautions may be required for populations at particular risk of infection or colonization by emerging XDR (eXDR), defined in our country as carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci. Our ability to detect and identify eXDR carriers early and ensure their follow-up, through effective communication between all those involved, is a significant challenge for controlling their spread. Thus, the French High Committee for Public Health has updated and standardized all French existing recommendations concerning the prevention of the cross-transmission of these bacteria, and these recommendations are summarized in this review. The recommendations are based on scientific and operational knowledge up to 2013. Different preventive strategies are recommended for patients found to be carrying eXDR and those who are considered to be at risk of having eXDR because of a history of contact. The local context, the experience of the infection control team, the different times at which detection of eXDR takes place (during admission, hospitalization, etc.) and the epidemiological situation (sporadic cases, clusters, outbreaks, widespread epidemic) must be included in risk assessments that in turn inform the control measures that should be applied in each clinical circumstance.
Copyright © 2015 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenemase-producing Enterobacteriaceae (CPE); Extensively drug-resistant bacteria (XDR); Multidrug-resistant bacteria (MDR); Vancomycin-resistant enterococci (VRE)

Mesh:

Year:  2015        PMID: 25986165     DOI: 10.1016/j.jhin.2015.04.002

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  15 in total

1.  Adverse effects of isolation: a prospective matched cohort study including 90 direct interviews of hospitalized patients in a French University Hospital.

Authors:  B Guilley-Lerondeau; C Bourigault; A-C Guille des Buttes; G Birgand; D Lepelletier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-09       Impact factor: 3.267

2.  Control of emerging extensively drug-resistant organisms (eXDRO) in France: a survey among infection preventionists from 286 healthcare facilities.

Authors:  D Lepelletier; J C Lucet; P Astagneau; B Coignard; S Vaux; C Rabaud; B Grandbastien; P Berthelot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-10       Impact factor: 3.267

3.  Outbreaks caused by vancomycin-resistant Enterococcus faecium in hematology and oncology departments: A systematic review.

Authors:  Nikos Ulrich; Ralf-Peter Vonberg; Petra Gastmeier
Journal:  Heliyon       Date:  2017-12-28

4.  The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.

Authors:  Jean-Winoc Decousser; Paul-Louis Woerther; Claude-James Soussy; Marguerite Fines-Guyon; Michael J Dowzicky
Journal:  Antimicrob Resist Infect Control       Date:  2018-05-30       Impact factor: 4.887

5.  First molecular characterization of related cases of healthcare-associated infections involving multidrug-resistant Enterococcus faecium vanA in Algeria.

Authors:  Sonia Benammar; Alix Pantel; Fabien Aujoulat; Messaoud Benmehidi; René Courcol; Jean-Philippe Lavigne; Sara Romano-Bertrand; Hélène Marchandin
Journal:  Infect Drug Resist       Date:  2018-09-17       Impact factor: 4.003

6.  Medical evacuation from abroad of critically ill patients: A case report and ethical issues.

Authors:  Jérôme Allyn; Nathalie Coolen-Allou; Bénédicte de Parseval; Thomas Galas; Olivier Belmonte; Nicolas Allou; Guillaume Miltgen
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

7.  Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria.

Authors:  Giorgia Battipaglia; Florent Malard; Marie Therèse Rubio; Annalisa Ruggeri; Anne Claire Mamez; Eolia Brissot; Federica Giannotti; Remy Dulery; Anne Christine Joly; Minh Tam Baylatry; Marie Jeanne Kossmann; Jacques Tankovic; Laurent Beaugerie; Harry Sokol; Mohamad Mohty
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

8.  Outbreak of OXA-48-producing Enterobacterales in a haematological ward associated with an uncommon environmental reservoir, France, 2016 to 2019.

Authors:  Sarah Jolivet; Jeanne Couturier; Xavier Vuillemin; Cyril Gouot; Didier Nesa; Marine Adam; Eolia Brissot; Mohamad Mohty; Rémy A Bonnin; Laurent Dortet; Frédéric Barbut
Journal:  Euro Surveill       Date:  2021-05

9.  Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015.

Authors:  Sandra Fournier; Laure Desenfant; Catherine Monteil; Michèle Nion-Huang; Christian Richard; Vincent Jarlier
Journal:  Euro Surveill       Date:  2018-02

10.  Assessing the role of inter-facility patient transfer in the spread of carbapenemase-producing Enterobacteriaceae: the case of France between 2012 and 2015.

Authors:  Narimane Nekkab; Pascal Crépey; Pascal Astagneau; Lulla Opatowski; Laura Temime
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.